Navigation Links
Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
Date:10/21/2009

QUINCY, Mass., Oct. 21 /PRNewswire/ -- Myriant Technologies LLC (Myriant), a privately-held, biotech developer and manufacturer of renewable biochemicals, announced the formation of its Science Advisory Board and the appointment of distinguished Board members. Board members individually and collectively will provide broad insight into all aspects of the technology and business of converting renewable biomass feedstocks into valuable chemicals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091021/NE96331LOGO )

Collectively, the Board members have outstanding credentials as scientists in the biotechnology fields of specific interest to Myriant, including: molecular biology, genetic and metabolic pathway engineering, micro-organism development and related fermentation process development.

Myriant's Science Advisory Board members include:

  • Dr. Stephen J. Benkovic, Evan Pugh Professor and Eberly Chair in Chemistry at Penn State University, and member of the National Academy of Sciences and its Institute of Medicine;
  • Dr. Joseph Glas, Executive Vice President and Advisory Board Chairman, Myriant;
  • Dr. Lonnie Ingram, Distinguished Professor, Department of Microbiology and Cell Science, University of Florida, and Director, Florida Center for Renewable Chemicals and Fuels, and member of the National Academy of Sciences;
  • Dr. Jan Westpheling, Professor, Department of Genetics, University of Georgia; and
  • Dr. Huimin Zhao, Professor, Centennial Endowed Chair of Chemical and Biomolecular Engineering, University of Illinois.

"I am honored and we are fortunate to have such an exceptional group of scientists as advisors to Myriant," said Stephen J. Gatto, Chairman and Chief Executive Officer of Myriant. "Under the leadership of Dr. Joe Glas, I have great confidence that we will reap immediate and lo
'/>"/>

SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
2. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
5. OriGene Technologies Acquires Marligen Biosciences
6. China Medical Technologies Announces the SFDA Approval for its SPR System
7. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
8. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
9. TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions
10. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
11. Variation Biotechnologies Names Jeff Baxter CEO

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...O recently announced that Dr. Dominique Hebrault w...cess Analytical Technology (PAT) in Green Chemistr.... , (PRWEB) November 20, ... Technology (PAT) in Green Chemistry and Green Eng...l Technology (PAT) case studies will be presented ...
(Date:11/19/2009)...-FirstCall/ -- Omeros Corporation (Nasdaq: OMER )...he third quarter ended September 30, 2009. For the...orted a net loss of $3.9 million, or $1.34 per sha...$2.54 per share, for the same period in 2008. For ...any reported a net loss of $15.5 million, or $5.29...
(Date:11/19/2009)...e-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), ...ter to its shareholders, discussing the Company,s ...maceuticals Holdings, Inc. (CHBP), an integrated b...public of China. The merger gives NeoStem a contro...o. Ltd., CHBP,s primary operating subsidiary and a...
(Date:11/19/2009)...ember 19 MONITORING FORCE GmbH,ann... Flibanserin in the,indication treatment-relevant ... for orphan drug status designation with the Europ...inesia is a complication of the mainstay,treatment...ome of those,affected, since it may be disabling f...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...search and development funding has exceeded expect...o a new report. The state had set a target of $3.3... th nationally in private R&D spending per capita...be hard-pressed to find an industry to match the g...Ward, president of NorthStar Economics , an econ...
...ts at Chippewa Valley Technical College in Eau Cla...icro-level surface analysis to firms or organizati...ojects. , ,Instructor Hans Mikelson says three stu...t completion by December 15, 2005. Mikelson belie...tron microscope are the best likely partners. A m...
...Facilities, Inc. , a global leader in the design, ...on networks, technology networks and security syst...provide network design and deployment services for...al Wi-Fi network. Working together with communicat...n with Madison Gas & Electric, WFI will deploy a W...
Other Biology Technology:New report says Wisconsin R&D spending exceeding expectations 2
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...e fungus for food, have many remarkable qualities.... farmers, like their human counterparts, depend on...ow. The finding, reported this week (Nov. 20) in t...wn symbiosis between ants and bacteria and provide...ominate the American tropics and subtropics. , W...
(Date:11/19/2009)...ies of the world. It is widely used for human cons... also is considered an exemplar plant species for ...enome architecture. The authors of the research pr...description of the B73 maize genome to probe some ...lant biology. The ten papers consider maize centro...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Like humans, ants use bacteria to make their gardens grow 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Pharmacyclics Files Registration Statement for Rights Offering 12375 1Pharmacyclics Files Registration Statement for Rights Offering 12375 2Pharmacyclics Files Registration Statement for Rights Offering 12375 3Pharmacyclics Files Registration Statement for Rights Offering 12375 4MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations Discovery Through Phase IIa 47427 1MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations Discovery Through Phase IIa 47427 2MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations Discovery Through Phase IIa 47427 3MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations Discovery Through Phase IIa 47427 4Entremed Presents Results of ENMD 2076 Phase 1 Study in Advanced Cancer Patients 4497 1Entremed Presents Results of ENMD 2076 Phase 1 Study in Advanced Cancer Patients 4497 2Entremed Presents Results of ENMD 2076 Phase 1 Study in Advanced Cancer Patients 4497 3Entremed Presents Results of ENMD 2076 Phase 1 Study in Advanced Cancer Patients 4497 4
...nly collapse, it can be due to hereditary cardiac ...Hospital have now discovered a genetic modificatio...l. Just one "false" amino acid can give zebrafish ...akeup similar to that of humans, these defects cou...sufficiency is not just a disease that results fro...
... for rejoicing, many people who have undergone the...disease unfortunately suffer from a physical and m...ely dysfunctional symptom ranges from fatigue and ...possible brain damage. In CHEMOBRAIN: HOW CANCER ... $18.98), a clear, concise guide for cancer patien...
...affected with retinitis pigmentosa (RP), a disease...s to blindness. Now, a University of Missouri rese...and humans for two different forms of RP. This dis...rapies that will benefit both cats and humans. , ... blindness in humans also cause retinal blindness ...
Other Biology News:Why 'lazy Susan' has a weak heart 2ChemoBrain: How cancer therapies can affect your mind 2Cats' eye diseases genetically linked to diseases in humans 2
QCapture PRO from QImaging
Mouse Anti-Ia Antigen Monoclonal Antibody, Biotin Conjugated, Clone CIa from Abcam
Rabbit Anti-Dardarin Antibody, Unconjugated from CHEMICON
Mouse Anti-Mannose Receptor Monoclonal Antibody, Biotin Conjugated, Clone 15-Feb from Abcam
Biology Products: